Screener
Rhythm Pharmaceuticals, Inc. RYTM Increase Decrease In Derivative Liabilities
Increase Decrease In Derivative Liabilities at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDerivativeLiabilities.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Non-cash interest expense | 4,577 | 5,408 |
| Non-cash accretion & amortization of short-term investments | (1,436) | (1,787) |
| Non-cash rent expense | 113 | 110 |
| Change in fair value of embedded derivative liability | 330 | 80 |
| Foreign currency (gain) loss | 1,352 | — |
| Other non-cash items | 178 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (8,110) | 687 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s increase decrease in derivative liabilities?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported increase decrease in derivative liabilities of $330K in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s increase decrease in derivative liabilities changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s increase decrease in derivative liabilities increased by 312.5% year-over-year, from $80K to $330K.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s increase decrease in derivative liabilities?
- Over 2 years (2022 to 2025), Rhythm Pharmaceuticals, Inc.'s increase decrease in derivative liabilities has grown at a 90.8% compound annual growth rate (CAGR), from -$250K to -$910K.
- What does increase decrease in derivative liabilities mean?
- This measures the net change in liabilities arising from derivative financial instruments held by the company. It reflects fluctuations in the fair value of these instruments that impact the company's overall risk profile.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s increase decrease in derivative liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude